Boehringer Ingelheim 2024 sales up forex-adj 6.1%

Reuters

Apr 02

Boehringer Ingelheim 2024 sales up forex-adj 6.1%

By Patricia Weiss

INGELHEIM, Germany, April 2 (Reuters) - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.

Group sales reached 26.8 billion euros ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.

Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly LLY.N, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%.

Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's AZN.L Farxiga.

Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.

Boehringer is in a collaboration with Denmark's Zealand Pharma ZELA.CO to develop a weight loss drug that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.

For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.

($1 = 0.9261 euros)

(Writing by Ludwig BurgerEditing by Madeline Chambers)

((ludwig.burger@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524345990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524345990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524345990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524345990","market":"nz","top_or_hot":-1,"title":"Boehringer Ingelheim 2024 sales up forex-adj 6.1%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Boehringer Ingelheim 2024 sales up forex-adj 6.1% </title></head><body><p>By Patricia Weiss</p><p>\n<span>INGELHEIM, Germany, April 2 (Reuters)</span><span> - </span>Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.</p><p>Group sales reached 26.8 billion euros  ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.</p><p>\n<span>Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly <span>LLY.N</span>, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%. </span>\n</p><p>Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's <span>AZN.L</span> Farxiga.</p><p>\n<span>Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.</span>\n</p><p><span>Boehringer is in a collaboration with Denmark's Zealand Pharma <span>ZELA.CO</span> to develop a weight loss </span><span>drug</span><span> that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.</span></p><p>\n<span>For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.</span> </p><p>($1 = 0.9261 euros)</p><p> (Writing by Ludwig BurgerEditing by Madeline Chambers)</p><p> ((ludwig.burger@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boehringer Ingelheim 2024 sales up forex-adj 6.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoehringer Ingelheim 2024 sales up forex-adj 6.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-02 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Boehringer Ingelheim 2024 sales up forex-adj 6.1% </title></head><body><p>By Patricia Weiss</p><p>\n<span>INGELHEIM, Germany, April 2 (Reuters)</span><span> - </span>Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.</p><p>Group sales reached 26.8 billion euros  ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.</p><p>\n<span>Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly <span>LLY.N</span>, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%. </span>\n</p><p>Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's <span>AZN.L</span> Farxiga.</p><p>\n<span>Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.</span>\n</p><p><span>Boehringer is in a collaboration with Denmark's Zealand Pharma <span>ZELA.CO</span> to develop a weight loss </span><span>drug</span><span> that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.</span></p><p>\n<span>For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.</span> </p><p>($1 = 0.9261 euros)</p><p> (Writing by Ludwig BurgerEditing by Madeline Chambers)</p><p> ((ludwig.burger@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN.UK","symbol_name":"阿斯利康制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nL5N3QF1AS:1","article_id":"2524345990","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524345990","pubTimestamp":1743585503,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Boehringer Ingelheim 2024 sales up forex-adj 6.1% By Patricia Weiss. INGELHEIM, Germany, April 2  - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.Group sales reached 26.8 billion euros  , the family-owned, unlisted drugmaker said in a statement.Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly LLY.N, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%.Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's AZN.L Farxiga.Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.Boehringer is in a collaboration with Denmark's Zealand Pharma ZELA.CO to develop a weight loss drug that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obes","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AZN.UK":"阿斯利康制药","LLY":"礼来"},"translate_title":"勃林格殷格翰2024年销售额按外汇调整后增长6.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9,"AZN.UK":0.9},"content_text":"Boehringer Ingelheim 2024 sales up forex-adj 6.1% By Patricia Weiss\nINGELHEIM, Germany, April 2 (Reuters) - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.Group sales reached 26.8 billion euros  ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.\nBoehringer's Jardiance group of products, managed in a partnership with Eli Lilly LLY.N, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%. \nJardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's AZN.L Farxiga.\nAnnual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.\nBoehringer is in a collaboration with Denmark's Zealand Pharma ZELA.CO to develop a weight loss drug that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.\nFor 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects. ($1 = 0.9261 euros) (Writing by Ludwig BurgerEditing by Madeline Chambers) ((ludwig.burger@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}